The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance (Q38037329)

27 August 2017

title

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance (English)

1 reference

27 August 2017

0 references

1 reference

Peter Bouwman

1 reference

27 August 2017

Jos Jonkers

series ordinal

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 September 2012

1 reference

27 August 2017

published in

Nature Reviews Cancer

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

587-598

1 reference

The DNA Damage Response: Making It Safe to Play with Knives

27 August 2017

cites work

1 reference

Principles of ubiquitin and SUMO modifications in DNA repair.

31 March 2020

1 reference

Brca1 controls homology-directed DNA repair

31 March 2020

1 reference

BRCA2 is required for homology-directed repair of chromosomal breaks

31 March 2020

1 reference

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

31 March 2020

1 reference

Identification of the breast cancer susceptibility gene BRCA2

31 March 2020

1 reference

The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer

31 March 2020

1 reference

Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer

31 March 2020

1 reference

Mutation of a mutL homolog in hereditary colon cancer

31 March 2020

1 reference

Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications

31 March 2020

1 reference

Platinum resistance: the role of DNA repair pathways

31 March 2020

1 reference

Targeted Radiosensitization of Cells Expressing Truncated DNA Polymerase β

31 March 2020

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

31 March 2020

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

31 March 2020

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

31 March 2020

1 reference

Genetic Interactions in Cancer Progression and Treatment

31 March 2020

1 reference

A DNA Damage Response Screen Identifies RHINO, a 9-1-1 and TopBP1 Interacting Protein Required for ATR Signaling

31 March 2020

1 reference

A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance

31 March 2020

1 reference

A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers

31 March 2020

1 reference

Modeling the therapeutic efficacy of p53 restoration in tumors

31 March 2020

1 reference

Restoration of p53 function leads to tumour regression in vivo

31 March 2020

1 reference

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

31 March 2020

1 reference

Stage-specific sensitivity to p53 restoration during lung cancer progression.

31 March 2020

1 reference

Selective activation of p53-mediated tumour suppression in high-grade tumours

31 March 2020

1 reference

The pathological response to DNA damage does not contribute to p53-mediated tumour suppression

31 March 2020

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

31 March 2020

1 reference

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

31 March 2020

1 reference

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

31 March 2020

1 reference

A decade of exploring the cancer epigenome — biological and translational implications

31 March 2020

1 reference

Translating p53 into the clinic.

31 March 2020

1 reference

p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage

31 March 2020

1 reference

DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization

31 March 2020

1 reference

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

31 March 2020

1 reference

Chk1 and Chk2 kinases in checkpoint control and cancer

31 March 2020

1 reference

New insights into checkpoint kinase 1 in the DNA damage response signaling network

31 March 2020

1 reference

DNA damage-induced activation of p53 by the checkpoint kinase Chk2

31 March 2020

1 reference

Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription

31 March 2020

1 reference

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

31 March 2020

1 reference

Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas

31 March 2020

1 reference

Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo

31 March 2020

1 reference

The combined status of ATM and p53 link tumor development with therapeutic response

31 March 2020

1 reference

In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma

31 March 2020

1 reference

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

31 March 2020

1 reference

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

31 March 2020

1 reference

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

31 March 2020

1 reference

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

31 March 2020

1 reference

Targeting base excision repair for chemosensitization

31 March 2020

1 reference

Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy

31 March 2020

1 reference

Error-prone translesion synthesis mediates acquired chemoresistance

31 March 2020

1 reference

Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control

31 March 2020

1 reference

Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability

31 March 2020

1 reference

Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response

31 March 2020

1 reference

Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining

31 March 2020

1 reference

SIRT1 Regulates UV-Induced DNA Repair through Deacetylating XPA

31 March 2020

1 reference

Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C

31 March 2020

1 reference

Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice

31 March 2020

1 reference

SIRT1 deacetylates APE1 and regulates cellular base excision repair

31 March 2020

1 reference

SIRT1 regulates the function of the Nijmegen breakage syndrome protein

31 March 2020

1 reference

Human SIRT6 promotes DNA end resection through CtIP deacetylation

31 March 2020

1 reference

Genomic instability and aging-like phenotype in the absence of mammalian SIRT6

31 March 2020

1 reference

Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis

31 March 2020

1 reference

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

31 March 2020

1 reference

Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage

31 March 2020

1 reference

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.

31 March 2020

1 reference

Multidrug resistance in cancer: role of ATP-dependent transporters

31 March 2020

1 reference

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

31 March 2020

1 reference

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator

31 March 2020

1 reference

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

31 March 2020

1 reference

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

31 March 2020

1 reference

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

31 March 2020

1 reference

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

31 March 2020

1 reference

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

31 March 2020

1 reference

BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.

31 March 2020

1 reference

PALB2 is an integral component of the BRCA complex required for homologous recombination repair

31 March 2020

1 reference

PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.

31 March 2020

1 reference

PALB2 links BRCA1 and BRCA2 in the DNA-damage response

31 March 2020

1 reference

Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

31 March 2020

1 reference

Spontaneous functional correction of homozygous Fanconi anaemia alleles reveals novel mechanistic basis for reverse mosaicism

31 March 2020

1 reference

The first 30 years of p53: growing ever more complex

31 March 2020

1 reference

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

31 March 2020

1 reference

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

31 March 2020

1 reference

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

31 March 2020

1 reference

Chemosensitivity linked to p73 function

31 March 2020

1 reference

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

31 March 2020

1 reference

Allele-specific tumor spectrum in pten knockin mice

31 March 2020

1 reference

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

31 March 2020

1 reference

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

31 March 2020

1 reference

BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity

31 March 2020

1 reference

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

31 March 2020

1 reference

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.

31 March 2020

1 reference

Identification of BRCA1-IRIS, a BRCA1 locus product

31 March 2020

1 reference

Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1

31 March 2020

1 reference

BRCA1-IRIS Overexpression Promotes Cisplatin Resistance in Ovarian Cancer Cells

31 March 2020

1 reference

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

31 March 2020

1 reference

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

31 March 2020

1 reference

Nucleotide excision repair- and polymerase eta-mediated error-prone removal of mitomycin C interstrand cross-links

31 March 2020

1 reference

The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links

31 March 2020

1 reference

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

31 March 2020

1 reference

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

31 March 2020

1 reference

Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia.

31 March 2020

1 reference

Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway

31 March 2020

1 reference

Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells

31 March 2020

1 reference

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

31 March 2020

1 reference

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

31 March 2020

1 reference

A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency

31 March 2020

1 reference

Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair

31 March 2020

1 reference

Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells

31 March 2020

1 reference

Limiting the persistence of a chromosome break diminishes its mutagenic potential

31 March 2020

1 reference

53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer

31 March 2020

1 reference

DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1

31 March 2020

1 reference

53BP1, a mediator of the DNA damage checkpoint

31 March 2020

1 reference

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer

31 March 2020

1 reference

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

31 March 2020

1 reference

Hallmarks of 'BRCAness' in sporadic cancers

31 March 2020

1 reference

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

31 March 2020

1 reference

Gene expression profiling predicts clinical outcome of breast cancer

31 March 2020

1 reference

31 March 2020

1 reference

Do predictive signatures really predict response to cancer chemotherapy?

31 March 2020

1 reference

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

31 March 2020

1 reference

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

31 March 2020

1 reference

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

31 March 2020

1 reference

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

31 March 2020

1 reference

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

31 March 2020

1 reference

Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model

31 March 2020

1 reference

In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression

31 March 2020

1 reference

Topoisomerase levels determine chemotherapy responsein vitroandin vivo

31 March 2020

1 reference

Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair

31 March 2020

1 reference

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

31 March 2020

1 reference

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors

31 March 2020

1 reference

Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?

31 March 2020

1 reference

High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?

31 March 2020

1 reference

The resurgence of platinum-based cancer chemotherapy

31 March 2020

1 reference

Drug candidates derailed in case of mistaken identity

31 March 2020

1 reference

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

31 March 2020

1 reference

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

31 March 2020

1 reference

Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations

31 March 2020

1 reference

Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2

31 March 2020

1 reference

Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.

31 March 2020

1 reference

Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability

31 March 2020

1 reference

A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.

31 March 2020

1 reference

A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.

31 March 2020

1 reference

Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors

31 March 2020

1 reference

12 December 2020

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

1 reference

12 December 2020

Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint

1 reference

12 December 2020

Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2

1 reference

12 December 2020

Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance

1 reference

12 December 2020

Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3342

1 reference

Dimensions Publication ID

27 August 2017

1003979939

0 references

1 reference